HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Roy A Mariuzza Selected Research

Natural Cytotoxicity Triggering Receptor 3

6/2015Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
4/2011Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Roy A Mariuzza Research Topics

Disease

17Neoplasms (Cancer)
01/2022 - 01/2002
6Septic Shock (Toxic Shock Syndrome)
01/2013 - 09/2006
5Melanoma (Melanoma, Malignant)
11/2013 - 05/2002
2Infections
12/2016 - 10/2012
2Autoimmune Diseases (Autoimmune Disease)
11/2012 - 11/2007
2Multiple Sclerosis
03/2011 - 09/2005
2Purpura Fulminans
01/2011 - 07/2007
1COVID-19
10/2022
1Type 2 Diabetes Mellitus (MODY)
12/2021
1Tuberculosis (Tuberculoses)
01/2017
1Chronic Hepatitis C
12/2016
1Necrosis
07/2015
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2013
1Foodborne Diseases
07/2007
1Human Influenza (Influenza)
09/2006

Drug/Important Bio-Agent (IBA)

9Peptides (Polypeptides)IBA
11/2013 - 05/2002
7LigandsIBA
01/2020 - 01/2002
6SuperantigensIBA
01/2013 - 09/2006
5T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2022 - 09/2005
5HLA-DR1 Antigen (HLA DR1 Antigen)IBA
09/2012 - 05/2002
5Histocompatibility Antigens Class IIIBA
09/2012 - 09/2005
4EpitopesIBA
10/2022 - 04/2007
4CytokinesIBA
01/2011 - 09/2006
3Proteins (Proteins, Gene)FDA Link
01/2022 - 11/2016
3Triose-Phosphate Isomerase (Triosephosphate Isomerase)IBA
09/2012 - 05/2002
3AntigensIBA
06/2010 - 05/2002
2HLA-A2 Antigen (HLA A2 Antigen)IBA
10/2022 - 01/2022
2Antiviral Agents (Antivirals)IBA
12/2016 - 10/2012
2Monoclonal AntibodiesIBA
12/2016 - 06/2015
2Natural Cytotoxicity Triggering Receptor 3IBA
06/2015 - 04/2011
2HLA-DR4 Antigen (HLA DR4 Antigen)IBA
11/2013 - 03/2011
2Myelin Basic ProteinIBA
03/2011 - 09/2005
1SARS-CoV-2 spike proteinIBA
10/2022
1Pharmaceutical PreparationsIBA
12/2021
1valiolamineIBA
12/2021
1voglibose (Basen)IBA
12/2021
1NectinsIBA
01/2019
1LipidsIBA
01/2017
1Broadly Neutralizing AntibodiesIBA
12/2016
1Complement System Proteins (Complement)IBA
12/2016
1Interleukin-8 (Interleukin 8)IBA
07/2015
1Interleukin-10 (Interleukin 10)IBA
07/2015
1Interleukin-12 (IL 12)IBA
07/2015
1Membrane Proteins (Integral Membrane Proteins)IBA
06/2015
1VaccinesIBA
11/2013
1LectinsIBA
08/2013
1Thomsen-Friedenreich antigenIBA
08/2013
1Polysaccharides (Glycans)IBA
08/2013
1AntibodiesIBA
08/2013
1Carbohydrate Tumor-Associated Antigens (Antigens, Tumor-Associated Carbohydrate)IBA
01/2013
1peptidoglycan recognition proteinIBA
01/2013
1ExotoxinsIBA
01/2013
1Pathogen-Associated Molecular Pattern MoleculesIBA
10/2012
1Methicillin (Metin)FDA Link
01/2011
1Indicators and Reagents (Reagents)IBA
01/2011
1PhosphopeptidesIBA
06/2010
1Cadherins (E-Cadherin)IBA
07/2009
1Bacterial ToxinsIBA
08/2007
1Interleukin-2 (IL2)IBA
07/2007
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/2007
1ZincIBA
09/2006
1Hemagglutinins (Hemagglutinin)IBA
09/2006
1staphylococcal enterotoxin IIBA
09/2006
1HLA Antigens (Human Leukocyte Antigens)IBA
09/2005
1Natural Killer Cell ReceptorsIBA
06/2003
1Natural Cytotoxicity Triggering Receptor 2IBA
06/2003
1EnzymesIBA
05/2002
1Neoplasm Antigens (Tumor Antigens)IBA
05/2002

Therapy/Procedure

4Immunotherapy
01/2019 - 05/2002
2Cell- and Tissue-Based Therapy (Cell Therapy)
01/2022 - 01/2020
2Therapeutics
11/2013 - 05/2002